Lisinopril—a commonly used angiotensin-converting enzyme inhibitor (ACEI)—significantly reduces MCP-1 levels in the urine of patients with diabetic nephropathy by reducing MCP-1 expression in renal tubular epithelial cells, leading to reduced monocyte migration and improved renal function [96]. This evidence concerns the gene CCL2 and diabetic kidney disease.